Cargando…
The Global Programme to Eliminate Lymphatic Filariasis: Health Impact after 8 Years
BACKGROUND: In its first 8 years, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) achieved an unprecedentedly rapid scale-up: >1.9 billion treatments with anti-filarial drugs (albendazole, ivermectin, and diethylcarbamazine) were provided via yearly mass drug administration (MDA) t...
Autores principales: | Ottesen, Eric A., Hooper, Pamela J., Bradley, Mark, Biswas, Gautam |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556399/ https://www.ncbi.nlm.nih.gov/pubmed/18841205 http://dx.doi.org/10.1371/journal.pntd.0000317 |
Ejemplares similares
-
The Economic Benefits Resulting from the First 8 Years of the Global Programme to Eliminate Lymphatic Filariasis (2000–2007)
por: Chu, Brian K., et al.
Publicado: (2010) -
Assessing Progress in Reducing the At-Risk Population after 13 Years of the Global Programme to Eliminate Lymphatic Filariasis
por: Hooper, Pamela J., et al.
Publicado: (2014) -
The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000–2014)
por: Turner, Hugo C., et al.
Publicado: (2016) -
A refined and updated health impact assessment of the Global Programme to Eliminate Lymphatic Filariasis (2000–2020)
por: Turner, Hugo C., et al.
Publicado: (2022) -
Progress and Impact of 13 Years of the Global Programme to Eliminate Lymphatic Filariasis on Reducing the Burden of Filarial Disease
por: Ramaiah, K. D., et al.
Publicado: (2014)